Home › Meningeal Carcinomatosis › NCT06417710

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients (18 years or more), female or male
* Histologically confirmed diagnosis of extra-CNS primary solid cancer
* Diagnosis of leptomeningeal metastases confirmed or probable per EANO ESMO criteria
* Performance status compatible with enrolment into clinical trials
* Ability to consent
* Signed informed consent form from patient
* Participation in a parallel clinical trial is allowed in this non-interventional study

Exclusion Criteria:

* Inability to give informed consent
* Inability to adhere to recommended follow-up according to the treating physician

Vulnerable participants will not be included.

About the study

The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.

What is being tested

• Neurological Assessment (other)

Sponsor: University of Zurich · Participants: 200 · Started: Jan 30, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT06417710

Locations in the U.S.

Conditions

• Meningeal Carcinomatosis
• Meningeal Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.